Wide Ranks

FATE

Fate Therapeutics, Inc.

3.17

Top Statistics
Market Cap 361 M Forward PE -1.94 Revenue Growth 58.10 %
Current Ratio 8.29 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.9900 Enterprise / Revenue 12.13 Price To Sales Trailing12 Months 26.85
Profitability
Profit Margins 0.00 % Operating Margins -1703.87 %
Balance Sheet
Total Cash 296 M Total Cash Per Share 2.61 Total Debt 98 M
Total Debt To Equity 27.32 Current Ratio 8.29 Book Value Per Share 3.18
All Measures
Short Ratio 720.00 % Message Board Id finmb_39268712 Shares Short Prior Month 16 M
Return On Equity -0.4659 City San Diego Uuid 98fe3f7f-5aa9-30d5-b866-ea8a0474dc72
Previous Close 2.68 First Trade Date Epoch Utc 1 B Book Value 3.18
Beta 1.88 Total Debt 98 M Volume 5 M
Price To Book 0.9965 Fifty Two Week Low 1.96 Total Cash Per Share 2.61
Total Revenue 13 M Shares Short Previous Month Date 1 B Target Median Price 5.00
Audit Risk 7 Max Age 86400 Recommendation Mean 2.44
Sand P52 Week Change 0.3133 Operating Margins -1703.87 % Target Mean Price 6.31
Net Income To Common -178231008 Short Percent Of Float 0.1047 Implied Shares Outstanding 113 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 6 M
Average Volume10days 6 M Total Cash 296 M Next Fiscal Year End 1 B
Revenue Per Share 0.1230 Held Percent Insiders 0.0217 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 8
Regular Market Previous Close 2.68 Target Low Price 3.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 2.88 Open 2.68 Free Cashflow -58500376
State CA Dividend Yield 0.00 % Return On Assets -0.2211
Time Zone Short Name EST Board Risk 3 Trailing Eps -1.64
Day Low 2.68 Address1 12278 Scripps Summit Drive Shares Outstanding 113 M
Compensation Risk 10 Price Hint 4 Target High Price 10.00
Website https://www.fatetherapeutics.com 52 Week Change 0.2731 Average Volume 2 M
Forward Eps -1.68 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 809.60 % Is_sp_500 False Regular Market Day High 3.27
Profit Margins 0.00 % Debt To Equity 27.32 Fifty Two Week High 8.83
Day High 3.27 Shares Short 10 M Regular Market Open 2.68
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 12.13
Revenue Growth 58.10 % Shares Percent Shares Out 0.0912 Operating Cashflow -131712000
Currency USD Time Zone Full Name America/New_York Market Cap 361 M
Is_nasdaq_100 False Zip 92131 Quote Type EQUITY
Industry Biotechnology Long Name Fate Therapeutics, Inc. Overall Risk 8
Regular Market Day Low 2.68 Held Percent Institutions 1.02 Current Price 3.17
Enterprise To Ebitda -0.9900 Financial Currency USD Current Ratio 8.29
Industry Disp Biotechnology Number Of Analyst Opinions 13 Country United States
Float Shares 98 M Two Hundred Day Average 4.33 Governance Epoch Date 1 B
Enterprise Value 163 M Price To Sales Trailing12 Months 26.85 Forward PE -1.94
Regular Market Volume 5 M Ebitda -164668992 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.

The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.

Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors.

The company has a collaboration and option agreement with Ono Pharmaceutical Co.

Ltd.

for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer.

Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.